

Coexistence of Pemphigus Vulgaris and Psoriasis in a Middle Aged Man

Sara Saniee¹, Armaghan Ghare Aghaji Zare^{1,*}

¹Assistant professor at Tabriz university of medical sciences, Tabriz, Iran

*Corresponding author: Armaghan Ghare Aghaji Zare, Dermatology department, Sina hospital, Tabriz, Iran; Email: derm@drzareh.com; Tel: +989125762716.

Abstract

Psoriasis and pemphigus vulgaris are two inflammatory and autoimmune diseases. Their concomitant occurrence in one patient is very rare. We describe a 57-year-old patient with a history of severe plaque type psoriasis for 2 years. After a few months, he presented with disseminated bullae and mucosal erosions which were documented as pemphigus vulgaris. Both of the diseases were successfully controlled with rituximab, prednisolone and weekly methotrexate.

Keywords: Psoriasis, Pemphigus Vulgaris, Rituximab

Introduction

The coexistence of psoriasis vulgaris and bullous diseases has been described in less than 100 literature¹⁻¹⁴. The triggering factor in association of psoriasis and pemphigus vulgaris is unknown and may be more than coincidence and may be explained on an immunologic basis. The effects of one immune-mediated skin disease may influence the occurrence of the other one. Possible mechanisms include reduced barrier function of the skin and antigen modification, altered regulation of T-cell activity, plasminogen activator abnormalities and side effects of therapies. The concept of 'epitope spreading' by exposing new antigens due to cutaneous damage may explain development of bullous disorders. Psoriasis also has been associated with other autoimmune diseases like crohn, lupus erythematosus, rumatoidarthritis and celiac disease¹⁵. Methotrexate is first-line systemic therapy for psoriasis as it is highly efficacious for severe disease and all clinical variant of psoriasis. In some patients with pemphigus vulgaris, methotrexate has been used as an immunosuppressive agent. Also rituximab increasingly is used for pemphigus vulgaris. Using as adjuvant therapy led to a complete remission in most of the patients with refractory pemphigus vulgaris^{16,17}. Concomitant use of methotrexate and rituximab is approved in patients with rheumatoid arthritis. In the literature, the coexistence of psoriasis vulgaris and bullous diseases has been treated with cyclosporine monotherapy^{2,3},

etanercept¹, corticosteroids and cyclophosphamide⁴, corticosteroid and azathioprine⁵, corticosteroid monotherapy, methotrexate monotherapy. We present a patient with a history of severe plaque type psoriasis treated with Neotigason that developed flaccid skin and mucosal bullae documented as pemphigus vulgaris by histopathology and direct immunofluorescence. Both of the diseases were successfully controlled by rituximab 500 mg/ IV/ weekly for 4 weeks, prednisolone daily and methotrexate weekly. Maybe immunosuppressive agents directed at cellular and humoral responses can result in clinical improvement of both conditions.

Case Report

A 57-year-old man presented to the Dermatology clinic of Sina hospital in July. 2015, with a 2-month history of erosions and crusted lesions and flaccid bullae of the oral mucosa and skin. These lesions began to erupt on his oral mucosa with eventual spread to the scalp, face, limbs include palmoplantar skin (Figure 1-3). In physical exam his Nickolsky sign was also positive. His Past medical history was included plaque type psoriasis from 2 years ago. His drug history was included oral Neotigason (30 mg/day) and topical corticosteroid. He was receiving Neotigason from 9 month ago. On presentation to our clinic, biopsy was done. Histology and direct immunofluorescence assay confirmed diagnose of pemphigus vulgaris. He was admitted in dermatology unit. Prior to treatment, chest X-ray,

PPD (purified protein derivate skin test), CBC, liver function tests, renal function tests, FBS, lipid profile, hepatitis B and C serologic profiles were done. All lab data was normal. Patient was received rituximab 500 mg/ IV/ weekly for 4 weeks, prednisolone daily and methotrexate weekly.



Figure 1. Tongue, lip and buccal mucosae erosion



Figures 2. disseminated flaccid bullae and erosion on trunk and limbs

Methotrexate was started with dose of 5 mg/ weekly and increased by 2.5 mg/ weekly and then continue with dose of 12.5 mg/ weekly. Prednisolone was started with dose of 75mg/ daily, then gradually tapered over 5 months, and reached maintenance dose of 7.5 mg/ daily. At this time, we checked IgG autoantibody against desmoglein 3 and desmoglein 1 by ELISA, both of them were negative and below 20 (anti Dsg1:0.2 and anti Dsg3:0.7). Now, the patient is in remission and No flare-up (neither psoriasis lesions nor pemphigus lesions) have been observed after 12 months treatment.




Figure 4. (A) Blister in the skin shows suprabasilar acantholysis, papillae protrude into the blister cavity and there is moderate perivascular infiltration. (B) Few rounded up acantholytic cells are seen in blister cavity, attachment of basal cells to the basement membrane has made the appearance of 'row of tombstones'.

Discussion

For the past two decades, psoriasis has been regarded as a T cell driven disease. Recent studies have shown that the role of Th17 in its pathogenicity has also a role in autoimmunity; however, to date no true autoantigen has been definitively identified¹⁵.

Pemphigus vulgaris is an autoimmune blistering disease that is characterized by finding of IgG autoantibody against desmoglein 3 and desmoglein 1.

We treated our patient with prednisolone, methotrexate and rituximab. The diseases were successfully controlled by rituximab 500 mg/ IV/ weekly for 4 weeks, prednisolone daily and methotrexate weekly. It seems that immunosuppressive agents directed at cellular and humoral responses can result in clinical improvement of both conditions.

Conflicts of interest

Authors declare no conflict of interests.

References

1. Daulat S, Detweiler JG, Pandya AG. Development of pemphigus vulgaris in a patient with psoriasis treated with etanercept. *J Eur Acad Dermatol Venereol.* 2009 Apr; 23(4):483-4.
2. Rallis E, Stavropoulos P, Christofidou E, et al. Pemphigus vulgaris with plaque-type psoriasis successfully treated with cyclosporine monotherapy. *Am J Clin Dermatol.* 2011 Aug 1; 12(4):283-4.
3. Caldarola G, Carbone A, De Simone C, et al. Development of pemphigus vulgaris in a patient with psoriasis treated with cyclosporine. *J Am Acad Dermatol.* 2010; 63: 356–357.
4. Hasse-Cieślińska M, Dmochowski M, Bowszyc-Dmochowska M, et al. A case of sporadic pemphigus foliaceus in teenage girl with psoriasis vulgaris. *Pol Merkur Lekarski.* 2005 May; 18(107):568-70.
5. HyuckHoon Kwon, In Ho Kwon, Jin Ho Chung, et al. Pemphigus Foliaceus Associated with Psoriasis during the Course of Narrow-Band UVB Therapy: A Simple Coincidence? *Ann Dermatol.* 2011; 23(3): 281-284.
6. Masmoudi A, HadjTaieb H, Ben Ayed M, et al. Tunisian erythematous pemphigus associated with psoriasis in two sisters. *Ann Dermatol Venereol.* 2006 Feb; 133(2):184-5.
7. Stavropoulos PG, Kostakis PG, Papakonstantinou AM, et al. Coexistence of psoriasis and pemphigus after enalapril intake. *Dermatology.* 2003; 207(3):336-7.
8. Kurtzman DJ, Christopher M, Lian F, et al. A blistering response: concurrent psoriasis and pemphigus foliaceus. *Am J Med.* 2015 Jan; 128(1):24-6.
9. Aytakin S, Inalöz HS, Harman M, et al. Coexistence of psoriasis vulgaris and bullous disorders. *J Eur Acad Dermatol Venereol.* 1999 Mar; 12(2):185-7.
10. Morita E, Amagai M, Tanaka T, et al. A case of herpetiform pemphigus coexisting with psoriasis vulgaris. *Br J Dermatol.* 1999 Oct; 141(4):754-5.
11. Yokoo M, Oka D, Ueki H. Coexistence of psoriasis vulgaris and pemphigus foliaceus. *Dermatologica.* 1989; 179(4):222-3.
12. Perez GL, Agger WA, Abellera RM, et al. Pemphigus foliaceus coexisting with IgA nephropathy in a patient with psoriasis vulgaris. *Int J Dermatol.* 1995 Nov; 34(11):794-6.
13. Panzarella K, Camisa C. Coexistence of superficial pemphigus and psoriasis. *Cutis.* 1996 Jun; 57(6):414-8.
14. Grunwald MH, David M, Feuerman EJ. Coexistence of psoriasis vulgaris and bullous diseases. *J Am Acad Dermatol.* 1985 Aug; 13(2 Pt 1):224-8.
15. Peter CM van de Kerkhof, Frank O Nestle, psoriasis. In: Jean L. Bolognia, Joseph L. Jorizzo, and Julie V. Schaffer, editors. *Dermatology.* 3rd Edition. Elsevier; 2012. P 135-155.
16. Ahmed AR, Spigelman Z, Cavacini LA, et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. *N Engl J Med.* 2006; 355:1772-9.
17. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. *N Engl J Med.* 2007; 357:545-52.